Lenvatinib Mesylate

製品コードS5240 バッチS524004

化学情報

	Synonyms	E7080 mesylate	Storage (From the date of receipt)	3 years -20°C powder
	化学式	C₂₁H₁₉ClN₄O₄.CH₄O₃S
	分子量	522.96	CAS No.	857890-39-2
Solubility (25°C)*	体外	DMSO	30 mg/mL (57.36 mM)
		Water	Insoluble
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Lenvatinib Mesylate is a synthetic, orally available tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (Kit (c-Kit)), and rearranged during transfection (RET (c-RET)). Lenvatinib Mesylate has potential antineoplastic activity.
in vitro	E7080 is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.

製品説明

Lenvatinib Mesylate is a synthetic, orally available tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (Kit (c-Kit)), and rearranged during transfection (RET (c-RET)). Lenvatinib Mesylate has potential antineoplastic activity.

in vitro

E7080 is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.

プロトコル(参考用のみ)

細胞アッセイ	細胞株	HUVECs
	濃度	5.2 nM (SCF) & 5.1 nM (VEGF)
	反応時間
	実験の流れ	HUVECs were treated with various concentrations of E7080 for an hour and stimulated with either SCF or VEGF (20 ng/mL) for 5 min.
動物実験	動物モデル	Female BALB/c nude mice
	投薬量	30 & 100 mg/kg
	投与方法	p.o.

参考

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma [ Nat Commun, 2024, 15(1):1754]	PubMed: 38409200
Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma [ J Hepatocell Carcinoma, 2023, 10:697-712]	PubMed: 37138764
Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest [ Discov Oncol, 2023, 14(1):26]	PubMed: 36821012
Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma [ Cancer Res, 2022, canres.2934.2021]	PubMed: 35767704
circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis [ Clin Transl Med, 2022, 12(1):e662]	PubMed: 35051313
EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli [ Cell Death Dis, 2022, 13(4):351]	PubMed: 35428350
Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis [ Sci Rep, 2022, 12(1):12546]	PubMed: 35869130
Regorafenib and reactive metabolite of sunitinib activate inflammasomes: Implications for multi tyrosine kinase inhibitor-Iiduced immune related adverse events [ Pharmazie, 2022, 77(2):54-58]	PubMed: 35209964
Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report [ Commun Med (Lond), 2022, 2:80]	PubMed: 35789568
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma [ J Immunother Cancer, 2021, 9(6)e002305]	PubMed: 34168004

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。